New pill aims to boost immune attack on Hard-to-Treat cancers
NCT ID NCT06425926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help the immune system fight cancer. Because this is a phase 1/2 study, the main focus is on safety and finding the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GIM-531 (an oral drug that targets regulatory T-cells) and anti-PD-1 (an immunotherapy)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early phase 1/2 trial with only 117 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects. It is too soon to know if it will work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Comprehensive Blood and Cancer Center
RECRUITINGBakersfield, California, 93309, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
HonorHealth Research Institute
RECRUITINGScottsdale, Arizona, 85258, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
RECRUITINGBillings, Montana, 59102, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Providence Medical Foundation
RECRUITINGFullerton, California, 92835, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tennessee Oncology, PLLC
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
RECRUITINGLos Angeles, California, 90025, United States
Contact Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94143, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Cincinnati Cancer Center
RECRUITINGCincinnati, Ohio, 45267, United States
Contact
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Weill Cornell Medicine - New York Presbyterian Hospital
RECRUITINGNew York, New York, 10065, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a blast of radiation make immunotherapy work better against kidney cancer?